Glycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus

References

1. ↵
   Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47: 1703–20.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381–9.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.

   OpenUrlCrossRefPubMedWeb of Science
5. Skyler JS. Diabetic complications: the importance of glucose control. Endocrin Metab Clin North Am 1996; 25: 243–54.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405–412.

   OpenUrlAbstract/FREE Full Text
7. ↵
   Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy. Arch Int Med 2008; 168: 2440–7.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet 2010; 376: 419–30.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial–revisited. Diabetes 2008; 57: 995–1001.

   OpenUrlAbstract/FREE Full Text
10. ↵
    American Diabetes Association. Standards of Medical Care in Diabetes –2010. Diabetes Care 2010; 33(Suppl 1): S1–S61.

    OpenUrlFREE Full Text
11. ↵
    Rigalleau V, Lasseur C, Raffaitin C, et al. Glucose control influences glomerular filtration rate and its prediction in diabetic subjects. Diabetes Care 2006; 29: 1491–5.

    OpenUrlAbstract/FREE Full Text
12. ↵
    National Kidney Foundation. Glomerular filtration rate (GRF). Available at: http://www.kidney.org/kidneydisease/ckd/knowGFR.cfm#chart. Accessed March 2010.
13. ↵
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703–12.

    OpenUrlAbstract/FREE Full Text
14. ↵
    Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145–51.

    OpenUrlCrossRefPubMedWeb of Science
15. Brosnahan G, Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. South Med J 2010; 103: 140–6.

    OpenUrlPubMed
16. ↵
    Barit D, Cooper ME. Diabetic patients and kidney protection: an attainable target. J Hypertens 2008; 26: S3–S7.

    OpenUrl
17. ↵
    Executive Committee, National Kidney Foundation. Clinical practice recommendation 3: Diabetes and chronic kidney disease in special populations. Am J Kidney Dis 2007; 49(2 Suppl 2): S120–30.

    OpenUrl
18. ↵
    Hirsch IB, Brownlee M. Beyond hemoglobin a1c –need for additional markers of risk for diabetic microvascular complications. JAMA 2010; 303: 2291–2.

    OpenUrlCrossRefPubMed
19. ↵
    Ritz E, Orth SR. Primary care: nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127–33.

    OpenUrlCrossRefPubMedWeb of Science